Overview

Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an incomplete response to MTX. The pharmacokinetics and immunogenicity profile of CDP870 will also be investigated to assess the extrapolability of foreign data to the Japanese population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Collaborator:
UCB Japan Co. Ltd.
Treatments:
Certolizumab Pegol